Abstract

To investigate the efficacy of linezolid in the treatment of pulmonary tuberculosis combined with severe pneumonia and its effect on the prognosis. 72 patients with pulmonary tuberculosis combined with severe pneumonia were selected in our hospital and random divided into control and observation group. Patients in both groups first received basic symptomatic treatment. On this basis, the control group was given isoniazid injection intravenously while the observation group was given linezolid glucose injection intravenously as an adjunctive treatment and both groups were treated continuously for 14 d. The clinical efficacy, bacterial clearance rate, immune function, cytokine levels and incidence of adverse reactions were compared between the two groups after 28 d treatment. The results showed that the total effective and bacterial clearance rate in the observation group were higher than those in the group (p<0.05) and the levels of cluster of differentiation 4, cluster of differentiation 8, cluster of differentiation 4/cluster of differentiation 8, immunoglobulin a and immunoglobulin g were increased while the levels of interleukin-6, interleukin-8 and tumour necrosis factor alpha were decreased in two groups after treatment (p<0.05) and the observation group was significantly different than that of the control group (p<0.05). The use of linezolid in the treatment of patients with tuberculosis combined with severe pneumonia is clinically effective and safe and is worthy of clinical application.